Loading…
Loading…
Can you talk about some consumer analog you'd point investors towards when you're thinking about long-term penetration for both the US and OUS for your weight loss product
Can Lilly achieve both goals of kind of preserving continuous innovation in obesity and having orfo be a drug for hundreds of millions of patients with the parity pricing model between the U.S. and...
What's Lilly's appetite to committing to launching new products at net parity pricing between the U.S. and Europe
Would long-term net pricing have to approach insulin levels for that to become a reality?
Are you implying that while you'll give additional discounts to the channel to improve access, that will be offset by improved adherence?
I am kind of curious why your Trope-two development strategy seems to be relatively conservative
what gets you more excited? The signal you're seeing with your TROP2 or the PD-1 VEGF class
What's the right cadence when you think about this going forward, not only for the rest of 2025
is a 25% tariff a reasonable expectation? Or do you expect the headline number to be higher
What are the ballpark components of that $25 billion figure, particularly for the TROP2 and the Daiichi ADCs
the data in second line plus NSCLC has been pretty underwhelming so far versus docetaxel. Your team confident that you can deliver a superior profile with your upcoming Phase three
I had a question on your upcoming Phase III EZH2 readout in CRPC. I'm surprised the study is more prominently flagged given the potential to extend the XTANDI franchise
Would it be fair to say that the bottom line earnings impact would be a single-digit percent basis with reasonable mitigation steps?
you don't actually test your bilayer formulation until the second half of your weight loss trial. Is that what your team is waiting on